Anti-Ischemic Efficacy of Trimetazidine , in an Animal Model of Insulin Resistance "Impact of the Associated Metabolic Abnormalit.ies and their Modulation by Captopril".

Abstract

The piperazine derivative, Trimetazidine (TMZ), is an anti-ischemic agent with a novel mechanism of action. Unlike conventional anti-ischemic agents which exert their effects through hemodynamic changes, TMZ exerts a local cytoprotective effect by switching myocardial cell metabolism during ischemia from lipid oxidation with its high oxygen demand to that of glucose oxidation with its low oxygen requirements, thus reducing the impact of the ischemic insult

The risk of ischemic heart disease is greatest among diabetics, with the insulin resistance syndrome. The increased risk of ischemic heart disease in such patients is not only attributable to the systemic metabolic abnormalities associated with the disease, but abnormalities in cardiac energy metabolism at the cellular level have also been implicated.